Drug news
NICE now finds Firmagon (degarelix) to be not cost effective as a prostate cancer treatment- Ferring
The National Institute for Care and Clinical Excellence (NICE) has reversed an earlier decision regarding Firmagon (degarelix) from Ferring and concluded that the drug is not a cost-effective treatment for advanced, hormone-dependent prostate cancer compared with the current standard of care. The independent Appraisal Committee of NICE had previously provisionally supported the drug’s use in patients with signs and symptoms of spinal cord compression, but clinical experts said that using the treatment at this stage would not be appropriate.